The Readout Loud

Episodes

• 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

  Nov 9, 2023

  Not summarized yet

• 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

  Nov 2, 2023

  Not summarized yet

• 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

  Oct 26, 2023

  Not summarized yet

• 279: Live from the 2023 STAT Summit

  Oct 19, 2023

  Not summarized yet

• 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

  Oct 12, 2023

  Not summarized yet

• 277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

  Oct 5, 2023

  Not summarized yet

• 276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

  Sep 28, 2023

  Not summarized yet

• 275: A thorny ALS debate at the FDA, and the promise of artificial wombs

  Sep 21, 2023

  Not summarized yet

• 274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

  Sep 14, 2023

  Not summarized yet

• 273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

  Sep 7, 2023

  Not summarized yet

• 272: Vivek's star turn, leaky drug data, & biotech as family business

  Aug 24, 2023

  Not summarized yet

• 271: Racing for gene therapy, a pioneering approval, & startups in the lurch

  Aug 18, 2023

  Not summarized yet

• 270: Your guide to Wegovy’s blockbuster heart study

  Aug 10, 2023

  Not summarized yet

• 269: Biotech layoffs, eye drug drama, & gene therapy milestones

  Aug 3, 2023

  Not summarized yet

• 268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

  Jul 27, 2023

  Not summarized yet

• 267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

  Jul 20, 2023

  Not summarized yet

• 266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

  Jul 13, 2023

  Not summarized yet

• 265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

  Jun 29, 2023

  Not summarized yet

• 264: Messy PBM conflicts, debatable vaccines, & the future of flu season

  Jun 22, 2023

  Not summarized yet

• 263: Biogen's messy board, Laronde's data problem, & the downside of a boom

  Jun 15, 2023

  Not summarized yet